Abiopharma

CNBX PHARMACEUTICALS INC. (CNBX)

Symbol	CNBX
Name	CNBX PHARMACEUTICALS INC.
Sector	UNDEFINED
Region	North America
Industry	-
Address	20814 United States MD #3 Bethesda Metro Center Suite 700
Telephone	(877) 424-2429
Fax	—
Email	—
Website	http://www.Cannabics.com
Incorporation	US
Incorporated On	—
Employees	—
Fiscal Year	8/31
Public Since	—
Exchanges	OTC;NASDAQ
Auditor	Elkana Amitai CPA;
Audit Status	AUDITED
Reporting Status	U.S. Reporting: SEC Reporting
CIK	0001343009
Description	CNBX Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company specializing in the discovery, development and commercialization of novel cannabinoid-based products and innovative technologies for the treatment of cancer. We combine the power of our proprietary technologies with the expertise of our leading scientists to unlock the medicinal properties of cannabis and its diversity of bioactive compounds. We have conducted thousands of tests on biopsies and cell lines in order to identify the physiologic impact of cannabinoids on cell cycle and cell death. Our core technology is a continuously evolving bioinformatics platform that utilizes high throughput screening technology, advanced data analytics, artificial intelligence and proprietary methodologies to rapidly examine the physiologic impact of multiple cannabinoid compounds on tumor cells. Additional info from OTC: CNBX Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company specializing in the discovery, development and commercialization of novel cannabinoid-based products and innovative technologies for the treatment of cancer. We combine the power of our proprietary technologies with the expertise of our leading scientists to unlock the medicinal properties of cannabis and its diversity of bioactive compounds. We have conducted thousands of tests on biopsies and cell lines in order to identify the physiologic impact of cannabinoids on cell cycle and cell death. Our core technology is a continuously evolving bioinformatics platform that utilizes high throughput screening technology, advanced data analytics, artificial intelligence and proprietary methodologies to rapidly examine the physiologic impact of multiple cannabinoid compounds on tumor cells.

2026-02-05 18:07

New Form SCHEDULE 13G/A - CNBX Pharmaceuticals Inc. Filed: 2026-02-05 AccNo: 0001753926-26-000272 Size: 15 KB

2026-01-14 13:55

CNBX Pharmaceuticals Inc. (CNBX) Files Form 10-Q

2025-12-01 13:17

New Form 10-K - CNBX Pharmaceuticals Inc. Filed: 2025-12-01 AccNo: 0001683168-25-008736 Size: 3 MB

2025-11-10 21:59

New Form SCHEDULE 13G/A - CNBX Pharmaceuticals Inc. Filed: 2025-11-10 AccNo: 0001753926-25-001728 Size: 15 KB

2025-08-13 20:06

New Form SCHEDULE 13G/A - CNBX Pharmaceuticals Inc. Filed: 2025-08-13 AccNo: 0001753926-25-001322 Size: 15 KB

2025-07-14 00:00

(57% Neutral) CNBX PHARMACEUTICALS INC. (CNBX) Reports 74% Loss Reduction for 2025-05-31

2025-05-14 01:07

New Form SCHEDULE 13G/A - CNBX Pharmaceuticals Inc. Filed: 2025-05-13 AccNo: 0001753926-25-000800 Size: 15 KB

2025-04-14 00:00

(57% Neutral) CNBX PHARMACEUTICALS INC. (CNBX) Reports 79% Loss Reduction for 2025-02-28

2025-02-13 21:07

New Form SCHEDULE 13G/A - CNBX Pharmaceuticals Inc. Filed: 2025-02-13 AccNo: 0001753926-25-000250 Size: 15 KB

2025-01-13 00:00

(57% Neutral) CNBX PHARMACEUTICALS INC. (CNBX) Reports 81% Loss Reduction for 2024-11-30